3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates

3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates

Intravenous induction hypnotics are the primary agents used to achieve rapid loss of consciousness for general anesthesia, procedural sedation, and total intravenous anesthesia (TIVA). Understanding their distinct receptor pharmacology, multi-compartment pharmacokinetics, hemodynamic profiles, and toxicity profiles is essential for safe anesthesia practice.

---

1. Pharmacokinetic Principles: Redistribution & Context-Sensitive Half-Time

Intravenous hypnotics distribute according to a three-compartment pharmacokinetic model:

• $V_1$ (Central Compartment): Intravascular volume and highly perfused vessel-rich organs (brain, heart, liver, kidneys), representing ~10% of body mass but receiving ~75% of cardiac output.
• $V_2$ (Fast Peripheral Compartment): Muscle and skin.
• $V_3$ (Slow Peripheral Compartment): Adipose tissue and poorly perfused tissues.

Redistribution vs. Elimination

Following a single IV induction bolus, awakening occurs within 5 to 10 minutes. This termination of effect is NOT due to hepatic metabolism or renal excretion, but rather to rapid redistribution of drug from the vessel-rich central compartment ($V_1$) to the muscle/fat peripheral compartments ($V_2$ and $V_3$), causing central nervous system drug concentrations to fall below the hypnotic threshold.

Context-Sensitive Half-Time (CSHT)

Definition: The time required for the central compartment (plasma) drug concentration to decrease by 50% following the termination of a continuous, steady-state IV infusion of a specified duration (the "context").

• Propofol: Exhibits a stable CSHT of <40 minutes even after prolonged continuous infusions lasting up to 8 hours. This occurs because rapid metabolic clearance (hepatic + extrahepatic) continuously clears drug from the central compartment while peripheral tissues slowly release stored drug.
• Thiopental & Diazepam: Demonstrate steep increases in CSHT with prolonged infusions because peripheral compartments saturate, and clearance is too slow to prevent high plasma concentrations upon redistribution back into $V_1$.
• Etomidate: Short CSHT (~20–30 minutes) due to rapid ester hydrolysis by hepatic and plasma esterases.
• Ketamine: Relatively short CSHT (~30–45 minutes) due to high clearance and large volume of distribution.

---

2. Propofol (2,6-Diisopropylphenol)

Formulation & Physicochemical Characteristics

• Vehicle: Highly lipophilic oil formulated in a 1% aqueous emulsion containing 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide (egg yolk lecithin).
• Allergy Considerations: Egg yolk contains lecithin (phosphatidylcholine), whereas true egg allergies are mediated by ovalbumin in egg whites. True soy allergy is directed against soy proteins, not refined soybean oil. Propofol is generally safe in patients with egg white allergy, but is avoided in cases of documented anaphylaxis to propofol emulsion components.
• Preservatives & Microbial Growth: Diprivan brand contains 0.005% disodium edetate (EDTA); generic formulations contain 0.025% sodium metabisulfite (can trigger bronchospasm in sulfite-sensitive asthmatics) or benzyl alcohol. Because the lipid emulsion supports rapid microbial growth, vials and prefilled syringes must be used within 6 to 12 hours of opening using strict aseptic technique.

Mechanism of Action

Propofol binds selectively to the $\beta$-subunit ($\beta_1, \beta_2, \beta_3$) of the pentameric $GABA_A$ receptor complex, acting as a positive allosteric modulator to increase the duration of channel opening in response to endogenous GABA. At higher concentrations, propofol directly gates and opens the $GABA_A$ chloride channel in the absence of GABA, causing neuronal hyperpolarization and profound CNS depression.

Organ System Effects

1. Central Nervous System:
   • Decreases Cerebral Metabolic Rate of Oxygen ($\downarrow CMRO_2$ by ~35–45%), Cerebral Blood Flow ($\downarrow CBF$), Intracranial Pressure ($\downarrow ICP$), and Intraocular Pressure ($\downarrow IOP$).
   • Produces burst suppression on electroencephalogram (EEG) at high doses; possesses potent anticonvulsant properties.
   • Myoclonic twitches or subcortical excitatory movements may occur upon induction (subcortical disinhibition, not true cortical epileptiform activity).
2. Cardiovascular System:
   • Profound systemic hypotension: Caused by direct arterial vasodilation (decreases Systemic Vascular Resistance, $\downarrow SVR$) and venodilation (decreases preload / venous return).
   • Direct negative inotropic effect (decreases myocardial intracellular $Ca^{2+}$ availability).
   • Blunts the arterial baroreceptor reflex: Prevents compensatory reflex tachycardia despite severe hypotension, occasionally resulting in profound bradycardia or asystole (especially when co-administered with opioids, $\beta$-blockers, or in elderly/hypovolemic patients).
3. Respiratory System:
   • Dose-dependent respiratory depression; induction doses produce central apnea in 25–35% of patients.
   • Blunts ventilatory responses to both arterial hypercapnia and hypoxemia.
   • Suppresses upper airway and pharyngeal reflexes: Superior to all other agents for laryngeal mask airway (LMA) insertion without neuromuscular blockade.
   • Causes bronchodilation by relaxing airway smooth muscle.
4. Unique Properties:
   • Antiemetic: Low-dose boluses (10–20 mg IV) or low-rate infusions (10–20 mcg/kg/min) directly suppress the chemoreceptor trigger zone (CTZ) and reduce postoperative nausea and vomiting (PONV).
   • Antipruritic: 10 mg IV relieves neuraxial opioid-induced and cholestatic pruritus.

Propofol Infusion Syndrome (PRIS)

PRIS is a catastrophic, often fatal syndrome resulting from impaired cellular mitochondrial fatty acid oxidation and oxidative phosphorylation uncoupling.

• Risk Factors: Infusions exceeding 4 to 5 mg/kg/h (67–83 mcg/kg/min) for >48 hours, critical illness, sepsis, severe head trauma, high exogenous catecholamine or corticosteroid administration, and pediatric ICU sedation.
• Pathophysiology: Inhibits entry of long-chain fatty acids into mitochondria (inhibits carnitine palmitoyltransferase-1) and blocks electron transport chain complexes I and IV, forcing cells into anaerobic metabolism.
• Clinical Manifestations:
  • Refractory, severe high-anion-gap lactic acidosis
  • Rhabdomyolysis with massive creatine kinase (CK) elevation and myoglobinuria
  • Acute renal failure and hyperkalemia
  • Hepatomegaly and hypertriglyceridemia (lipemic serum)
  • Cardiac dysrhythmias: Brugada-like ECG pattern (coved ST-segment elevation in V1–V3), right bundle branch block (RBBB), refractory bradycardia, cardiogenic shock, and asystole.
• Management: Immediate cessation of propofol infusion, aggressive supportive care, hemodialysis/CRRT for acid-base correction, and extracorporeal membrane oxygenation (ECMO) if cardiogenic shock ensues.

---

3. Etomidate (Carboxylated Imidazole Derivative)

Formulation & Dosing

• Structure: Carboxylated imidazole containing a chiral center (formulated as the active $R$-(+) enantiomer, which has 12-fold greater hypnotic activity than the $S$-(-) isomer).
• Vehicle: Formulated in 35% propylene glycol ($pH \approx 6.9$). Propylene glycol causes significant pain on injection, local irritation, thrombophlebitis, and transient hemolysis.
• Induction Dose: 0.2 to 0.3 mg/kg IV.

Mechanism of Action

Selective positive allosteric modulator of the $GABA_A$ receptor, binding specifically to the $\beta_2$ and $\beta_3$ subunits to enhance chloride conductance.

Organ System Effects & Adrenocortical Suppression

1. Cardiovascular System:
   • Exceptional hemodynamic stability: Minimal to no change in heart rate, mean arterial pressure, stroke volume, cardiac index, pulmonary artery pressure, or systemic vascular resistance.
   • Does not blunt autonomic baroreflexes or suppress sympathetic tone; myocardial oxygen supply/demand ratio is preserved.
   • Agent of choice for induction in patients with severe aortic stenosis, severe coronary artery disease, cardiomyopathy, congestive heart failure, or hypovolemic shock.
2. Central Nervous System:
   • Potent cerebral vasoconstrictor: Decreases $CMRO_2$ (~35–45%), $\downarrow CBF$, and $\downarrow ICP$, while maintaining mean arterial pressure, thereby preserving Cerebral Perfusion Pressure ($CPP = MAP - ICP$).
   • High incidence of myoclonus (30–60%): Caused by subcortical disinhibition of extrapyramidal pathways (not seizure activity). Can be attenuated by pretreatment with low-dose opioids (fentanyl 1–2 mcg/kg) or midazolam.
3. Endocrine Adrenocortical Suppression (Board Essential):
   • Etomidate causes dose-dependent, reversible inhibition of $11\beta$-hydroxylase (and to a lesser degree $17\alpha$-hydroxylase), the mitochondrial cytochrome P450 enzyme responsible for converting 11-deoxycortisol to cortisol and 11-deoxycorticosterone to aldosterone.
   • A single induction dose (0.3 mg/kg) suppresses cortisol and aldosterone synthesis and blunts the adrenocortical response to adrenocorticotropic hormone (ACTH) stimulation for 6 to 24 hours.
   • Continuous infusions are strictly contraindicated due to documented increased mortality in critically ill septic and trauma patients.
4. Gastrointestinal: High incidence of postoperative nausea and vomiting (PONV, up to 30–40%).

---

4. Ketamine (Phencyclidine Derivative)

Chirality & Formulation

• Structure: Arylcyclohexylamine structurally related to phencyclidine (PCP).
• Enantiomers: Commercial preparation in the US is a racemic mixture of $S-(+)$ and $R-(-)$ ketamine. The $S-(+)$ enantiomer (esketamine) has 3 to 4 times greater affinity for NMDA receptors, provides twice the analgesic potency, causes less emergence agitation, and exhibits faster hepatic clearance than the $R-(-)$ isomer.
• Induction Dosing: 1.0 to 2.0 mg/kg IV (or 4.0 to 6.0 mg/kg IM for uncooperative pediatric/trauma patients).

Mechanism of Action & Dissociative Anesthesia

• Primary Mechanism: Non-competitive antagonist of the NMDA ($N$-methyl-$D$-aspartate) receptor, binding open-channel to the phencyclidine ($PCP$) site inside the calcium-permeable cation pore, inhibiting glutamate activation.
• Also inhibits HCN1 (hyperpolarization-activated cyclic nucleotide-gated 1) channels, interacts with $\mu, \kappa, \delta$ opioid receptors, monoaminergic receptors, and muscarinic acetylcholine receptors.
• Dissociative Anesthesia: Electrophysiologically dissociates the limbic system (which processes emotion and pain awareness) from the thalamocortical sensory projection systems. The patient appears awake (eyes open with slow nystagmic gaze), has intact corneal and cough reflexes, but is cataleptic, profoundly amnestic, and insensitive to noxious surgical stimulation.

Organ System Effects

1. Cardiovascular System:
   • Indirect Sympathomimetic: Stimulates central sympathetic outflow and inhibits neuronal reuptake of norepinephrine, leading to increased heart rate, arterial blood pressure, cardiac output, systemic vascular resistance, and pulmonary vascular resistance (PVR).
   • Direct Myocardial Depressant: In patients with end-stage shock or chronic critically ill states where endogenous catecholamine stores are fully depleted, the direct negative inotropic effect of ketamine is unmasked, resulting in paradoxical hypotension and cardiac collapse.
2. Respiratory System:
   • Potent Bronchodilator: Relaxes bronchial smooth muscle via sympathetic $\beta_2$-stimulation and direct vagolytic antagonism; agent of choice for induction in severe acute status asthmaticus.
   • Preserves spontaneous ventilation and upper airway protective reflexes (though aspiration can still occur).
   • Increases upper airway secretions and salivation (often co-administered with an anticholinergic like glycopyrrolate 0.2 mg IV).
3. Central Nervous System:
   • Classically increases $CMRO_2$, $CBF$, $ICP$, and $IOP$ via cerebral vasodilation (historically avoided in closed-head injury or elevated ICP, though modern controlled normocapnic ventilation attenuates these increases).
   • Emergence delirium / psychotomimetic reactions occur in 10–30% of patients (vivid dreams, hallucinations, floating sensations, agitation). Prevention: Pretreatment with Midazolam (1–2 mg IV) or Propofol co-administration.

5. Barbiturates (Thiopental & Methohexital)

Mechanism & Chemistry

• Chemistry: Derived from barbituric acid. Thiobarbiturates have a sulfur atom at C2 (e.g., Thiopental), increasing lipid solubility and potency; Oxybarbiturates have an oxygen atom at C2 (e.g., Methohexital, Pentobarbital).
• Formulation: Dissolved in anhydrous sodium carbonate to maintain an alkaline $pH > 10.5$. When mixed with acidic drugs (such as rocuronium, vecuronium, or opioids), barbiturates immediately precipitate as insoluble free acids, occluding IV cannulas.
• Mechanism: Positive allosteric modulation of $GABA_A$ receptors at low concentrations; direct chloride channel opening and suppression of AMPA glutamate transmission at high concentrations.

Clinical Profiles & Porphyria Contraindication

• Methohexital (Brevital, 0.75–1.0 mg/kg IV): Gold standard induction agent for Electroconvulsive Therapy (ECT). Unlike propofol and thiopental (which shorten seizure duration), methohexital activates cortical epileptogenic foci, lowers the seizure threshold, and produces prolonged, high-quality therapeutic seizures.
• Intra-arterial Injection Hazard: Inadvertent intra-arterial injection of thiopental causes severe chemical endarteritis, crystal precipitation, intense vasoconstriction, platelet aggregation, and distal limb gangrene. Treatment: Leave arterial catheter in place; inject heparin, papaverine or procaine (vasodilator), lidocaine, and perform an immediate stellate ganglion block or brachial plexus sympathetic block.
• Absolute Contraindication: Acute Intermittent Porphyria, Variegate Porphyria, and Hereditary Coproporphyria. Barbiturates induce the rate-limiting hepatic enzyme $\delta$-aminolevulinic acid (ALA) synthetase, accelerating porphyrin accumulation and precipitating life-threatening neurovisceral crises (severe abdominal pain, peripheral neuropathy, paralysis, psychiatric derangements, and autonomic instability).

---

6. Dexmedetomidine (Selective $\alpha_2$-Adrenergic Agonist)

Pharmacology & Receptor Selectivity

• Structure: Imidazole compound with an $\alpha_2:\alpha_1$ receptor selectivity ratio of 1620:1 (compared to 220:1 for clonidine).
• Mechanism: Stimulates pre- and postsynaptic $\alpha_2$-adrenergic receptors. Sedative and hypnotic actions are mediated specifically by stimulating presynaptic $\alpha_2A$ receptors in the locus coeruleus of the brainstem, decreasing adenylyl cyclase activity, inhibiting central norepinephrine outflow, and disinhibiting the ventrolateral preoptic nucleus (VLPO).
• "Cooperative / Biomimetic Sedation": Induces a state resembling non-REM Stage 3 (N3) slow-wave sleep. Patients are easily arousable to verbal stimuli, cooperative with neurological assessments, and follow commands, then readily drift back to sleep when left undisturbed.

Clinical Effects & Hemodynamic Profile

• Respiratory: Zero to minimal respiratory depression; preserves ventilatory response to hypercapnia and preserves airway patency (ideal for awake fiberoptic intubation and weaning mechanical ventilation in the ICU).
• Analgesic-Sparing: Reduces intraoperative opioid requirements by 30–50% and provides potent anti-shivering effects ($0.5\ \mu\text{g/kg}$ IV).
• Biphasic Hemodynamic Response: Rapid IV bolus administration activates peripheral vascular $\alpha_2B$ receptors on vascular smooth muscle, causing transient vasoconstriction and hypertension with reflex bradycardia. This is followed by sustained central $\alpha_2A$-mediated sympatholysis, resulting in systemic hypotension and bradycardia.
• Dosing: Loading infusion of 0.5 to 1.0 mcg/kg over 10 minutes, followed by maintenance infusion of 0.2 to 0.7 mcg/kg/h.